Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26985730 | 0.91 | KDM4E (0.51) | KDM4EALDH1A1SMN1; SMN2HTT | |
| SCHEMBL26995685 | 0.90 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2SIGMAR1POLB | |
| SCHEMBL30831657 | 0.89 | PDK2 (0.43) | KDM4EALDH1A1SMN1; SMN2SIGMAR1GAA | |
| SCHEMBL26995652 | 0.89 | PDK2 (0.43) | KDM4EALDH1A1SMN1; SMN2SIGMAR1GAA | |
| SCHEMBL31506023 | 0.87 | BCHE (0.43) | KDM4EALDH1A1SMN1; SMN2GAAHRH3 | |
| SCHEMBL31755688 | 0.87 | BCHE (0.43) | KDM4EALDH1A1SMN1; SMN2GAAHRH3 | |
| SCHEMBL31506013 | 0.87 | BCHE (0.43) | KDM4EALDH1A1SMN1; SMN2GAAHRH3 | |
| SCHEMBL31755841 | 0.87 | BCHE (0.43) | KDM4EALDH1A1SMN1; SMN2GAAHRH3 | |
| SCHEMBL30831453 | 0.86 | PDK2 (0.42) | KDM4EALDH1A1SMN1; SMN2GAAHTT | |
| SCHEMBL26995637 | 0.86 | PDK2 (0.42) | KDM4EALDH1A1SMN1; SMN2GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | KDM4E 4602/4885ALDH1A1 1848/4885SMN1; SMN2 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.